NovaBridge Biosciences (FRA:0VY) ROE % Adjusted to Book Value: -25.82% (As of Dec. 2025)


FRA:0VY NovaBridge Biosciences FRA:0VY
23 GF Score
Price €1.66
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences ROE % Adjusted to Book Value?

NovaBridge Biosciences FRA:0VY -4.60% 23 ROE % Adjusted to Book Value is -25.82% as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

NovaBridge Biosciences's ROE % for the quarter that ended in Dec. 2025 was -50.34%. NovaBridge Biosciences's PB Ratio for the quarter that ended in Dec. 2025 was 1.95. NovaBridge Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -25.82%.

NovaBridge Biosciences ROE % Adjusted to Book Value Related Terms

NovaBridge Biosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences ROE % Adjusted to Book Value Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -9.50 -97.04 -102.32 -29.26 -10.41

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.94 -18.82 -9.63 -7.53 -25.82

FRA:0VY vs HUMA, DTIL, ORMP: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBridge Biosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's ROE % Adjusted to Book Value falls into.


FRA:0VY
23GF Score
NovaBridge Biosciences FRA:0VY
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences ROE % Adjusted to Book Value Calculation

NovaBridge Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-20.30% / 1.95
=-10.41%

NovaBridge Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-50.34% / 1.95
=-25.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -25.82% mean?
NovaBridge Biosciences (FRA:0VY) has a ROE % Adjusted to Book Value of -25.82% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' ROE % Adjusted to Book Value too high?
NovaBridge Biosciences' current ROE % Adjusted to Book Value is -25.82%. Overall, NovaBridge Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' ROE % Adjusted to Book Value compare to HUMA and DTIL?
NovaBridge Biosciences' ROE % Adjusted to Book Value of -25.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current ROE % Adjusted to Book Value is -25.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (FRA:0VY) has a current ROE % Adjusted to Book Value of -25.82%. The current ROE % Adjusted to Book Value is -25.82%. NovaBridge Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current ROE % Adjusted to Book Value is -25.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
23GF Score

Get the complete analysis for FRA:0VY

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66
Price